All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Withdrawal of belantamab mafodotin for RRMM in the US

Nov 23, 2022
Learning objective: After reading this article, learners will be able to cite a new development in the management of multiple myeloma.

On November 22, 2022, it was announced that the process for the withdrawal of the US marketing authorization for belantamab mafodotin has been initiated.1 Discussions with European Union health authorities are still ongoing and no official decision has been shared yet.1

Belantamab mafodotin is a monotherapeutic agent that previously received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

This withdrawal is based on results of the DREAMM-3 trial (NCT04162210), in which the primary endpoint of progression-free survival was not met, with a hazard ratio of 1.03 (95% confidence interval, 0.721.47) in a head-to-head comparison of belantamab mafodotin versus pomalidomide plus dexamethasone.2 A longer observed median progression-free survival of 11.2 months was seen with belantamab mafodotin, compared with 7 months for pomalidomide plus dexamethasone.2

The safety and tolerability profile of belantamab mafodotin was consistent with the established safety profile, with no new safety concerns.2

Patients already receiving belantamab mafodotin and enrolled on the FDA Risk Evaluation and Mitigation Strategy (REMS) program will be able to continue to receive the drug through a compassionate use program.3

Clinical trials with belantamab mafodotin are ongoing, with data from the DREAMM-7 and DREAMM-8 phase III clinical trials expected in 2023.2,3

  1.  GSK to stop selling blood cancer drug Blenrep in United States. Published Nov 22, 2022. Accessed Nov 22, 2022.
  2.  GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma. Published Nov 7, 2022. Accessed Nov 22, 2022.
  3.  GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization. Published Nov 22, 2022. Accessed Nov 22, 2022.


Subscribe to get the best content related to multiple myeloma delivered to your inbox